1. Double domain fusion improves the reverse transcriptase activity and inhibitor tolerance of Bst DNA polymerase.
- Author
-
Xiang R, Liu GY, Hou Y, Xie LX, Wang QS, and Hu SQ
- Subjects
- Animals, Recombinant Fusion Proteins genetics, SARS-CoV-2 drug effects, SARS-CoV-2 genetics, Swine, Nucleic Acid Amplification Techniques methods, Protein Domains, DNA-Directed DNA Polymerase genetics, DNA-Directed DNA Polymerase metabolism, Reverse Transcriptase Inhibitors pharmacology, COVID-19 virology, RNA, Viral genetics, RNA-Directed DNA Polymerase metabolism, RNA-Directed DNA Polymerase genetics, African Swine Fever Virus genetics, African Swine Fever Virus enzymology
- Abstract
To enhance the DNA/RNA amplification efficiency and inhibitor tolerance of Bst DNA polymerase, four chimeric Bst DNA polymerase by fusing with a DNA-binding protein Sto7d and/or a highly hydrophobic protein Hp47 to Bst DNA polymerase large fragment. One of chimeric protein HpStBL exhibited highest inhibitor tolerance, which retained high active under 0.1 U/μL sodium heparin, 0.8 ng/μL humic acid, 2.5× SYBR Green I, 8 % (v/v) whole blood, 20 % (v/v) tissue, and 2.5 % (v/v) stool. Meanwhile, HpStBL showed highest sensitivity (93.75 %) to crude whole blood infected with the African swine fever virus. Moreover, HpStBL showed excellent reverse transcriptase activity in reverse transcription loop-mediated isothermal amplification, which could successfully detect 0.5 pg/μL severe acute respiratory syndrome coronavirus 2 RNA in the presence of 1 % (v/v) stools. The fusion of two domains with different functions to Bst DNA polymerase would be an effective strategy to improve Bst DNA polymerase performance in direct loop-mediated isothermal amplification and reverse transcription loop-mediated isothermal amplification detection, and HpStBL would be a promising DNA polymerase for direct African swine fever virus/severe acute respiratory syndrome coronavirus 2 detection due to simultaneously increased inhibitor tolerance and reverse transcriptase activity., Competing Interests: Declaration of competing interest The authors declare that they have no competing financial interest associated with this manuscript., (Copyright © 2024 Elsevier B.V. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF